Form 4: Phathom Pharmaceuticals CEO Terrie Curran Sells Shares to Cover Tax Obligations

Phathom Pharmaceuticals' CEO, Terrie Curran, sold 19,109 shares of common stock on January 21, 2025, to satisfy tax withholding obligations related to the settlement of restricted stock units.

Summary

• On January 21, 2025, Terrie Curran, the President and CEO of Phathom Pharmaceuticals, sold 19,109 shares of the company's common stock.
• The sale was executed at a weighted average price of $6.5877 per share, with individual transactions ranging from $6.5855 to $6.6503.
• The purpose of the sale was to cover tax withholding obligations arising from the settlement of restricted stock units.
• Following the transaction, Curran directly owns 360,465 shares of Phathom Pharmaceuticals.
• Curran also indirectly owns 3,840.16 shares through a 401(k) plan.
• She also acquired 1,840 shares under the employee stock purchase plan in January 2025.

Sentiment

Score: 5

Explanation: Neutral sentiment. The filing simply reports a routine stock sale to cover tax obligations. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Positives

• The CEO's continued direct ownership of 360,465 shares demonstrates a continued investment in the company.
• The acquisition of 1,840 shares under the employee stock purchase plan in January 2025 shows participation in company programs.

Industry Context

This is a routine Form 4 filing, disclosing an insider transaction. Insider sales are common and can be for various reasons, including tax obligations, diversification, or personal financial planning. It's important to consider the context and overall trend of insider transactions when evaluating the significance of this sale.

Stakeholder Impact

• The sale of shares by the CEO could have a minor negative impact on shareholder sentiment, although it is likely to be minimal given the stated reason for the sale.

Key Dates